A compound of formula: wherein: X is selected from -C(R 9) 2 -, -N(R 10)-, -O-, and -S t - where t is 0, 1, or 2; Y and Z are independently selected from -C(R 9) 2 -, -N(R 10)-, -O-, -S t - where t is 0, 1, or 2, and a heterocyclic moiety which contains 1 to 3 heteroatoms independently selected from O, N and S; R 1 is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, heterocyclyl, heteroaryl, cyano, amino, alkoxy, and hydroxyl; R 2 and R 3 are hydrogen; R 4 is selected from alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl and haloalkyl; or R 4 is a 5-membered monocyclic heteroaryl moiety which contains 1 to 3 heteroatoms independently selected from O, N and S wherein the heteroaryl moiety may be substituted with one or more substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halo, cyano, amino, alkoxy, hydroxyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl and Q-L-R 4a, where R 4 is not pyrazole; Q is a direct bond, or a straight or branched alkylene chain; L is selected from -N(R 10)-, -O-, -C -, -C O-, -S t - where t is 0, 1, or 2, -CON(R 10)-, -N(R 10)CO-, -SO 2 N(R 10)-, -N(R 10)SO 2 -, and -N(R 10)CON(R 10)-; R 4a is selected from alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl; R 5 and R 6 are independently selected from hydrogen, alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkoxyalkyl, alkylaminoalkyl, and - R 7 -V-R 8 where V is selected from -N(R 10)-, or -O-; R 7 is a straight or branched alkylene chain; R 8 is selected from hydrogen, alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkoxyalkyl, and alkylaminoalkyl; R 9 is selected from hydrogen, alkyl, halo, and haloalkyl; R 10 is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, and haloalkyl; a stereoisomer, enantiomer or tautomer thereof, an isotopically enriched derivative thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is capable of inhibiting the activity of one or more TAM kinase. X is selected from -C(R 9) 2 -, -N(R 10)-, -O-, and -S t - where t is 0, 1, or 2; Y and Z are independently selected from -C(R 9) 2 -, -N(R 10)-, -O-, -S t - where t is 0, 1, or 2, and a heterocyclic moiety which contains 1 to 3 heteroatoms independently selected from O, N and S; R 1 is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, heterocyclyl, heteroaryl, cyano, amino, alkoxy, and hydroxyl; R 2 and R 3 are hydrogen; R 4 is selected from alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl and haloalkyl; or R 4 is a 5-membered monocyclic heteroaryl moiety which contains 1 to 3 heteroatoms independently selected from O, N and S wherein the heteroaryl moiety may be substituted with one or more substituents selected from alkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, halo, cyano, amino, alkoxy, hydroxyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl and Q-L-R 4a, where R 4 is not pyrazole; Q is a direct bond, or a straight or branched alkylene chain; L is selected from -N(R 10)-, -O-, -C -, -C O-, -S t - where t is 0, 1, or 2, -CON(R 10)-, -N(R 10)CO-, -SO 2 N(R 10)-, -N(R 10)SO 2 -, and -N(R 10)CON(R 10)-; R 4a is selected from alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, aryl, heteroaryl, and heterocyclyl; R 5 and R 6 are independently selected from hydrogen, alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkoxyalkyl, alkylaminoalkyl, and - R 7 -V-R 8 where V is selected from -N(R 10)-, or -O-; R 7 is a straight or branched alkylene chain; R 8 is selected from hydrogen, alkyl, aralkyl, alkenyl, aralkenyl, alkynyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, alkoxyalkyl, and alkylaminoalkyl; R 9 is selected from hydrogen, alkyl, halo, and haloalkyl; R 10 is selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, and haloalkyl; a stereoisomer, enantiomer or tautomer thereof, an isotopically enriched derivative thereof, or a pharmaceutically acceptable salt thereof, wherein said compound is capable of inhibiting the activity of one or more TAM kinase.